Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Selective serotonin reuptake inhibitors (SSRIs) including sertraline have been found to be effective in the treatment of generalized social phobia (GSP). However, virtually all of the current treatment studies with medicines, including the SSRIs, have excluded patients with social phobia who have other co-occurring conditions. In fact, 80% of individuals suffering with primary social phobia have at least one other anxiety. This study will evaluate the safety and efficacy of sertraline in the treatment of generalized social phobia with co-occurring anxiety and mood disorders.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years to 70 Years (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Outpatient with primary Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) GSP plus at least one of the following comorbid DSM-IV anxiety disorders:

panic disorder with agoraphobia

obsessive compulsive disorder

major depressive disorder

generalized anxiety disorder

Score on LSAS > 50

Score on MADRS < 25

Exclusion Criteria:

Any other primary AXIS-I diagnosis

Criteria for alcohol/substance abuse/dependence

History (Hx) of bipolar disorder, schizophrenia or other psychotic disorder

A comorbid Axis II cluster A personality disorder

Current increased risk of concomitant suicide

Allergy/previous intolerance during an adequate trial (50mg/day for minimum of 4 weeks) of sertraline

Participation in any clinical trial 30 days prior to entering the study

Unable to tolerate being free of/shows signs of withdrawal from benzodiazepines for 4 weeks